Chapter References

1. Moncrieff J., Wessely, S., and Hardy, R. (1998). Meta-analysis of trials comparing antidepressants with 'active placebos'. British Journal of Psychiatry, 172, 227-31.

2. Morris, J.B. and Beck, A.T. (1974). The efficacy of antidepressant drugs: a review of research. Archives of General Psychiatry, 30, 667-74.

3. Bielski, R.J. and Friedel, R.O. (1976). Prediction of tricyclic antidepressant response: a critical review. Archives of General Psychiatry, 33, 1479-89.

4. Joyce, P.R. and Paykel, E.S. (1989). Predictors of drug response in depression. Archives of General Psychiatry, 46, 89-99.

5. Paykel, E.S., Hollyman, J.A., Freeling, P., and Sedgwick, P.J. (1988). Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. Journal of Affective Disorders, 14, 83-95.

6. Stewart, J.W., Quitkin, F.M., Liebowitz, M.R., McGrath, P.J., Harrison, W.M., and Klein, D.F. (1983). Efficacy of desipramine in depressed outpatients: response according to Research Diagnostic Criteria and severity of illness. Archives of General Psychiatry, 40, 202-7.

7. Song, F., Freemantle, N., Sheldon, T.A., et al. (1993). Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. British Medical Journal, 306, 683-7.

8. Montgomery, S.A., Henry, J., McDonald, G., et al. (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. International Clinical Psychopharmacology, 9, 47-53.

9. Anderson, I.M. and Tomenson, B.M. (1995). Treatment discontinuation with selective serotonin reuptake inhibitors compared to tricyclic antidepressants: a meta-analysis. British Medical Journal, 310, 1433-8.

10. Hotopf, M., Hardy, R., and Lewis, G. (1997). Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. British Journal of Psychiatry, 170, 120-7.

11. Goodman, W.K., Price, L.H., Delgado, P.L., et al. (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of flovoxamine and desipramine. Archives of General Psychiatry, 47, 577-85.

12. Griest, J.H., Jeffferson, J.W., Kobak, K.A., Katzelnick, D.J., and Serlin, R.C. (1995). Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Archives of General Psychiatry, 52, 53-60.

13. Tyrer, P. (1976). Towards rational therapy with monoamine oxidase inhibitors. British Journal of Psychiatry, 128, 354-60.

14. Paykel, E.S. (1990). Monoamine oxidase inhibitors: when should they be used. In Dilemmas and difficulties in the management of psychiatric patients (ed. K. Hawton and P. Cowen), pp. 17-30. Oxford University Press.

15. Paykel, E.S. (1995). Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression. Acta Psychiatrica Scandinavica, 91 (Supplement 386), 22-7.

16. Paykel, E.S., West, P.S., Rowan, P.R., and Parker, R.R (1982). Influence of acetylator phenotype on antidepressant effects of phenelzine. British Journal of Psychiatry, 141, 243-8.

17. Paykel, E.S., Parker, R.R., Rowan, P.R., Rao, B.M., and Taylor, C.N. (1983). Nosology of atypical depression. Psychological Medicine, 13, 131-9.

18. Quitkin, F.M., McGrath, P.J., Steward, J.W., et al. (1990). Atypical depression, panic attacks, and response to amipramine and phenelzine: a replication. Archives of General Psychiatry, 47, 935-41.

19. Angst J. and Stabl M. (1992). Efficacy of moclobemide in different patient groups: a meta-analysis of studies. Psychopharmacology, 106, S109-13.

20. Paykel, E.S. (ed.) (1992). The handbook of affective disorders (2nd edn). Churchill Livingstone, Edinburgh.

21. Bloom, F.E. and Kupfer, D.J. (ed.) (1995). Psychopharmacology: the fourth generation of progress. Raven Press, New York.

22. Frazer, A. (1997). Antidepressants. Journal of Clinical Psychiatry, 58 (Supplement 6), 9-25.

23. Davis, R., Whittington, R., and Bryson, H.M. (1997). Nefazodone: a review of its pharmacology and clinical efficacy in the management of major depression. Drugs, 53, 608-36.

24. Holliday, S.M. and Benfield, P. (1995). Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs, 49, 280-94.

25. Garattini, S. (1997). Pharmacology of amineptine, an antidepressant agent acting on the dopaminergic system: a review. International Clinical Psychopharmacology, 12, S15-19.

26. Ginestet, D. (1997). Efficacy of tianeptine in major depressive disorders with or without melancholia. European Neuropsychopharmacology, 7, S341-5.

27. Paykel, E.S. (1989). Treatment of depression: the relevance of research for clinical practice. British Journal of Psychiatry, 155, 754-63.

28. Janicak, P.G., Davis, J.M., Gibbons, R.D., Ericksen, S., Chang, S., and Gallagher, P. (1985). Efficacy of ECT: a meta-analysis. American Journal of Psychiatry, 142, 297-302.

29. Buchan, H., Johnstone, E., McPherson, K., Palmer, R.L., Crow, T.J., and Brandon, S. (1992). Who benefits from electroconvulsive therapy? Combined results of the Leicester and Northwick Park trials. British Journal of Psychiatry, 160, 355-9.

30. Mukherjee, S., Sackeim, H.A., and Schnur, D.B. (1994). Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. American Journal of Psychiatry, 151, 169-76.

31. DiFelia, G. and Raotma, H. (1975). Is unilateral ECT less effective than bilateral ECT? British Journal of Psychiatry, 126, 83-9.

32. Abrams, R., Taylor, M.A., Faber, R., Ts'o, T.O., Williams, R.A., and Almy, G. (1983). Bilateral versus unilateral electroconvulsive therapy: efficacy in melancholia. American Journal of Psychiatry, 140, 463-5.

33. Sackheim, H.A., Prudic, J., Devanand, D.P., et al. (1993). Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. New England Journal of Medicine, 328, 839-46.

34. George, M.S., Wassermann, E.M., Kimbrell, T.A., et al. (1997). Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. American Journal of Psychiatry, 154, 1752-6.

35. El-Mallakh, R. (1996). Lithium: actions and mechanisms, pp. 3-10. American Psychiatric Press, Washington, DC.

36. McElroy, S., Keck, P., and Pope, H. (1992). Valproate in the treatment of bipolar disorder: literature review and clinical guidelines. Journal of Clinical Psychopharmacology, 12, 42-52.

37. West, S., Keck, P., and McElroy, S. (1998). Valproate. In Mania: clinical and research perspectives (ed. P. Goodnick), pp. 301-18. American Psychiatric Press, Washington, DC.

38. Bowden, C., Brugger, A., Swann, A., et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. Journal of the American Medical Association, 271, 918-24.

39. Ketter, T., Post, R., Denicoff K., et al. (1998). Carbamazepine. In Mania: clinical and research perspectives (ed. P. Goodnick), pp. 263-300. American Psychiatric Press, Washington, DC.

40. Frank, E., Prien, R.F., Jarrett, R.B., et al. (1991). Conceptualisation and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse and recurrence. Archives of General Psychiatry, 48, 851-5.

41. Paykel, E.S. (1996). Tertiary prevention: longer-term drug treatment in depression. In The prevention of mental illness in primary care (ed. T. Kendrick, A. Tylee, and P. Freeling), pp. 281-93. Cambridge University Press.

42. Reimherr, F.W., Amsterdam, J.D., Quitkin, F.M., et al. (1998). Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. American Journal of Psychiatry, 155, 1247-53.

43. Haddad, P., Lejoyex, M., and Young, A. (1998). Antidepressant discontinuation reactions are preventable and simple to treat. British Medical Journal, 316, 1105-6.

44. Paykel, E.S. (1994). The place of antidepressants in long-term treatment. In Psychopharmacology of depression. British Association for Psychopharmacology Monograph 13 (ed. S.A. Montgomery and T.H. Corn), pp. 218-39. Oxford University Press, New York.

45. McElroy, S.L. and Weller, E. (1997). Psychopharmacological treatment of bipolar disorder across the lifespan. In Review of psychiatry, Vol. 16 (ed. L.J. Dickstein, M.B. Riba, and J.M. Oldham), pp. 124-78. American Psychiatric Press, Washington, DC.

46. Prien, R.F. (1992). Maintenance treatment. In Handbook of affective disorders (ed. E.S. Paykel), pp. 419-36. Churchill Livingstone, Edinburgh.

47. Goodwin, F.K. and Jamison, K.R. (1990). Manic depressive illness. Oxford University Press, New York.

48. Moncrieff, J. (1995). Lithium revisited: a re-examination of the placebo-controlled trials of lithium prophylaxis in manic-depressive disorder. British Journal of Psychiatry, 167, 569-73.

49. Goodwin, G. (1995). Lithium revisited: a reply. British Journal of Psychiatry, 167, 573-4.

50. Calabrese, J.R., Bowden, C. and Woyshville, M.J. (1995). Lithium and the anticonvulsants in the treatment of bipolar disorder. In Psychopharmacology: the fourth generation of progress (ed. F.E. Bloom and D.J. Kupfer), pp. 1099-111. Raven Press, New York.

51. Suppes, T., Baldessarini, R.J., Faedda, G.L., and Tohen, M. (1991). Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Archives of General Psychiatry, 48, 1082-8.

52. Baldessarini, R.J., Tondo, L., Floris, G. and Rudas, N. (1997). Reduced morbidity after gradual discontinuation of lithium treatment for bipolar I and II disorders: a replication study. American Journal of Psychiatry, 154, 551-3.

53. Keller, M.B., Lavori, P.W., Kane, J.M., et al. (1992). Subsyndromal symptoms in bipolar disorder: a comparison of standard and low serum levels of lithium. Archives of General Psychiatry, 49, 371-6.

54. Post, R.M. (1992). Anticonvulsants and novel drugs. In Handbook of affective disorders (ed. E.S. Paykel), pp. 387-418. Churchill Livingstone, Edinburgh.

55. Scott, J. (1995). Psychotherapy for bipolar disorders. British Journal of Psychiatry, 167, 581-8.

56. Scott, J. (1995). Editorial: psychological treatments for depression: an update. British Journal of Psychiatry, 167, 28-92.

57. Roth, T. and Fonagy, P. (1996). What works for whom?, pp. 57-103. Guilford Press, London.

58. Andrews, G. and Harvey, R. (1981). Does psychotherapy benefit neurotic patients. A re-analysis of the Smith, Glass and Miller data. Archives of General Psychiatry, 38, 1203-8.

59. Steinbrueck, S., Maxwell, S., and Howard, G. (1983). A meta-analysis of psychotherapy and drug therapy in the treatment of unipolar depression with adults. Journal of Consulting and Clinical Psychology, 51, 856-63.

60. Neitzel, M., Russell, R., Hemmings, K., and Gretter, M. (1987). Clinical significance of psychotherapy for unipolar depression: a meta-analytic approach to social comparison. Journal of Consulting and Clinical Psychology, 55, 156-61.

61. Dobson, K. (1988). A meta-analysis of the efficacy of cognitive therapy for depression. Journal of Consulting and Clinical Psychology, 57, 414-19.

62. Robinson, L., Berman, J., and Neimeyer, R. (1990). Psychotherapy for the treatment of depression: a comprehensive review of controlled outcome research. Psychological Bulletin, 108, 30-49.

63. Elkin, I., Shea, M., Watkins, J., et al. (1992). National Institute of Mental Health treatment of depression collaborative treatment programme. Archives of General Psychiatry, 46, 971-82.

64. Hollon, S., Shelton, R., and Davis, D. (1993). Cognitive therapy for depression: conceptual issues and clinical efficacy. Journal of Consulting and Clinical Psychology, 2, 270-5.

65. Hollon, S., DeRubeis, R., Evans, M., et al. (1992). Cognitive therapy and pharmacotherapy for depression: singly and in combination. Archives of General Psychiatry, 49, 774-81.

66. Klerman, G.L., DiMascio, A., Weissman, M.M., Prusoff, B.A., and Paykel, E.S. (1974). Treatment of depression by drugs and psychotherapy. American Journal of Psychiatry, 131, 186-91.

67. DiMascio, A., Weissman, M., Prusoff, B., Neu, C., Zwilling, M., and Klerman, G. (1979). Differential symptom reduction by drugs and psychotherapy in acute depression. Archives of General Psychiatry, 36, 1451-6.

68. McLean, P. and Hakstian, A. (1990). Relative endurance of unipolar depression treatment effects: longitudinal follow-up. Journal of Consulting and Clinical Psychology, 58, 482-8.

69. Hersen, M., Bellack, A., Himmelhoch, J., and Thase, M. (1984). Effects of social skills training, amitryptiline and psychotherapy on unipolar depressed women. Behaviour Therapy, 15, 21-40.

70. O'Leary, K. and Beach, S. (1990). Marital therapy: a viable treatment for depression and marital discord. American Journal of Psychiatry, 147, 183-6.

71. Jacobson, N., Dobson, K., Furzzetti, A., and Schmaling, K. (1991). Marital therapy as a treatment for depression. Journal of Consulting Clinical Psychology, 59, 547-57.

72. Conte, H., Plutchik, R., Wild, K., and Karasu, T. (1986). Combined psychotherapy and pharmacotherapy for depression. Archives of General Psychiatry, 43, 471-9.

73. Depression Guideline Panel (1993). Clinical practice guideline no 5: depression in primary care, Vol. 2. Treatment of major depression, pp. 71-123. US Department of Health and Human Services, AHCPR Publications, Rockville, MD.

74. Paykel, E.S. (1995). Psychotherapy, medication combinations and compliance. Journal of Clinical Psychiatry, 56 (Supplement 1), 24-30.

75. Weissman, M., Klerman, G., Prusoff, B., Sholomskas, D., and Padian, N. (1981). Depressed outpatients: results one year after treatment with drugs and/or interpersonal psychotherapy. Archives of General Psychiatry, 38, 51-5.

76. Evans, M., Hollon, S., DeRubeis, R., et al. (1992). Differential relapse following cognitive therapy and pharmacotherapy for depression. Archives of General Psychiatry, 49, 802-8.

77. Shea, M.T., Elkin, I., Linber, S., et al. (1992). Course of depressive symptoms over follow-up. Archives of General Psychiatry, 49, 782-7.

78. Blackburn, I., Euson, K., and Bishop, S. (1986). A two year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy or both. Journal of Affective Disorders, 109, 67-75.

79. Blackburn, I. and Moore, R. (1997). Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in outpatients with recurrent depression. British Journal of Psychiatry, 171, 328-34.

80. Fava, G.A., Grandi, S., Zielezny, M., Rafanelli, C., and Canestrari, R. (1996). Four-year outcome for cognitive behavioural treatment of residual symptoms in major depression. American Journal of Psychiatry, 153, 945-7.

81. Paykel, E.S., Scott, J., Teasdale, J., et al. (1999). Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Archives of General Psychiatry, 56, 829-35.

82. Frank, E., Kupfer, D., Perel, J., et al. (1990). Three year outcomes for maintenance therapies in recurrent depressions. Archives of General Psychiatry, 47, 1093-9.

83. Cochran, S. (1984). Preventing medical non-compliance in the outpatient treatment of bipolar affective disorders. Journal of Consulting and Clinical Psychology, 52, 873-8.

84. Sotsky, S., Glass, D., Shea, M., et al. (1991). Patient predictors of response to psychotherapy: findings in the NIMH treatment of depression collaborative research programme. American Journal of Psychiatry, 148, 997-1008.

85. De Lima, M.S., Hotoph, M., and Wessely, S. (1999). The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychological Medicine, 29, 1273-89.

86. Paykel, E.S. and Priest, R.G. (1992). Recognition and management of depression in general practice: consensus statement. British Medical Journal, 305, 1198-202.

87. Altschuler, L., Cohen, L., Szuba, M.P., Burt, V.K., Gitlin M., and Mintz, J. (1996). Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. American Journal of Psychiatry, 153, 592-606.

88. Scott, J. (1995). Review: managing treatment resistant depression. Primary Care Psychiatry, 1, 141-52.

89. Spiker, D., Weiss, J., Dealy, R., et al. (1985). The pharmacological treatment of delusional depression. American Journal of Psychiatry, 142, 430-6.

90. Freeman, C.P. (ed.) (1995). Council report CR39: the ECT handbook. The second report of the Royal College of Psychiatrist' Special Committee on ECT. Royal College of Psychiatrists, London.

91. Scott, J. (1988). Chronic depression. British Journal of Psychiatry, 153, 287-97.

92. Austin, M.-P., Souza, F.G.M., and Goodwin, G.M. (1991). Lithium augmentation in antidepressant-resistant patients: a quantitative analysis. British Journal of Psychiatry, 159, 510-14.

93. Katona, C.L.E., Abou-Saleh, M.T., Harrison, D.A., et al. (1995). Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. British Journal of Psychiatry, 166, 80-6.

94. Cowen, P. (1990). l-Tryptophan and the eosinophilia-myalgia syndrome. Psychiatric Bulletin, 14, 738-9.

95. Aronson, R., Offman, H.J., Joffe, R.T., and Naylor, D. (1996). Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Archives of General Psychiatry, 53, 842-8.

96. McAskill, R., Mir, S., and Taylor, D. (1998). Pindolol augmentation of antidepressant therapy. British Journal of Psychiatry, 173, 203-8.

97. Young, J.P.R., Lader, M.H., and Hughes, W.C. (1979). Controlled trial of trimipramine, monoamine oxidase inhibitors and combined treatment in depressed outpatients. British Medical Journal, 279, 1315-17.

98. Razani, J., White, J., Simpson, G., Sloane, R.B., Rebal, R., and Palmer, R. (1983). The safety and efficacy of combined amitriptyline and tranylcypramine antidepressant treatment. Archives of General Psychiatry, 40, 657-61.

99. Kocsis, J.H., Friedman, R.A., Markowitz, J.C., et al. (1996). Maintenance therapy for chronic depression: a controlled clinical trial of desipramine. Archives of General Psychiatry, 53, 769-74.

100. Paykel, E.S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J., and Barocka, A. (1995). Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine, 25, 1171-80.

101. Mindham, R.H., Howland, C., and Shepherd, M. (1973). An evaluation of discontinuation therapy with tricyclic antidepressants in depressive illness. Psychological Medicine, 3, 5-17.

102. Kupfer, D.J., Frank, E., Perel, J.M., et al. (1992). Five-year outcome for maintenance therapies in recurrent depression. Archives of General Psychiatry, 49, 769-73.

103. Kahn, D., Ross, R., and Rush, A. (1996). Expert consensus treatment guidelines for bipolar disorder. Journal of Clinical Psychiatry, 57, 1-8.

104. Freeman, M. and Stoll, A. (1998). Mood stabilizer combinations: a review of safety and efficacy. American Journal of Psychiatry, 155, 12-21.

105. Coryell, W., Solomon, D., Leon, A.C., et al. (1998). Lithium discontinuation and subsequent effectiveness. American Journal of Psychiatry, 155, 8895-8.

106. Scott, J. and DeRubeis, R. (2000). The role of cognitive therapy and psychosocial interventions in chronic and refractory mood disorders. In Textbook on refractory mood disorders. Cambridge University Press.

107. Clarkin, J., Glick, I., Haas, G., et al. (1990). A randomized clinical trial of inpatient family intervention: results for affective disorder. Journal of Affective Disorder, 18, 17-28.

108. Sackett, D. and Snow, J. (1979). The magnitude of compliance and non-compliance. In Compliance in health care (ed. R. Haynes, D. Taylor, and D. Sacket), pp. 11-22. Johns Hopkins University Press, Baltimore, MD.

109. Jamison, K., Gerner, R., and Goodwin, F. (1979). Patient and physician attitudes toward lithium: relationship to compliance. Archives of General Psychiatry, 45, 217-24.

Defeat Depression

Defeat Depression

Learning About How To Defeat Depression Can Have Amazing Benefits For Your Life And Success! Discover ways to cope with depression and melancholic tendencies! Depression and anxiety particularly have become so prevalent that it’s exceedingly common for individuals to be taking medication for one or even both of these mood disorders.

Get My Free Ebook

Post a comment